Jump to Main Contents

Home > Izumi O. Umeda, PhD

Izumi O. Umeda, PhDIzumi O. Umeda, PhD

梅田 泉

Molecular imaging is a technique that images living movements of molecules such as genes or proteins in the body dynamically. It may be referred to as "an image of the life". Our final goal is optimization and individualization of cancer treatment, and for this purpose, we are developing novel molecular imaging probes and techniques for non-invasive detection of cancer and its metastasis, by depicting molecular, metabolic and physiological characteristics of cancers.

Official title

  • Unit Head, Division of Functional imaging

Area of research

  • Molecular imaging
  • Nuclear medicine
  • Radiopharmaceutical scienc


  • Molecular imaging
  • Radionuclide therapy
  • Radiotheranostics
  • Hypoxia imaging
  • Imaging biomarker

Current main research theme

Imaging of intractable area in the cancer legion

Hypoxia is a feature of most solid tumors, and it is a negative and predictive factor of chemoresitance and radioresistance. In addition, in the hypoxic region, hypoxia inducible factor (HIF) is activated and promotes angiogenesis, vasculogenesis, invasiveness and metastasis. Therefore, hypoxic region is highly malignant region in the tumor. We are developing various hypoxia imaging probes which depict tumor hypoxia or HIF positive region.  Hypoxia imaging will contribute to not only optimization of radiotherapy and chemotherapy, but also development of new drugs targeting hypoxia.

Radiotheranostics for solid tumors

Radionuclide therapy involves certain types of radioisotopes bound to a specific carrier molecule that allows the radiopharmaceuticals to selectively be delivered to the target region. For the success of the radionuclide therapy for solid tumors, accumulation of large amounts of nuclides in the tumor is needed because solid tumors are generally less radiosensitive. At the same time, it is also necessary to minimalize radiation exposure of normal tissues. We devised a new strategy; i.e., to quickly expel radionuclides just from these normal tissues after accumulation, keeping high level in the tumor by combination of liposomes and radionuclide-ligand complexes. Now we are advancing our research on radionuclide therapy and radiotheranostics that enable to fight solid tumors.

Prediction and evaluation of drug efficacy by using molecular imaging technique

Molecular imaging allows visualization of drug behavior in the body, such as distribution, target accumulation, and target interaction. It also visualizes resultant response of drugs, such as inhibition of cell proliferation or apoptosis.  We aim at prediction and evaluation of drug efficacy by using molecular imaging technique. Development of imaging biomarker is included.

Multimodal imaging

Molecular imaging has some modality, such as MR imaging and optical imaging besides nuclear medicine imaging. We also wrestle for development of the new diagnostic imaging beyond the limit of the single modality by combining them

Collaborative research themes

  • Development of new imaging probes, TR
  • Radionuclide therapy, Radiotheranostics
  • Development of bioimaging marker for prediction and evaluation of drug efficacy
  • In vivo imaging using small animals


ioumeda●east.ncc.go.jp(● replace to @)

Brief History

  • 1981  B.S. in Pharmaceutical Science, Chiba University     
  • 1983  M.S. in Pharmaceutical Science, Chiba University
  • 1989  Ph.D. in Pharmaceutical Science, Chiba University
  • 1983-2007  Assistant Professor, Associate Professor, Department of Pharmaceutical Science, Teikyo University
  • 2007-2012  Section Head, Radionuclide Imaging Section, Functional Imaging Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
  • 2012-2016  Unit Head, Division of Functional Imaging, Research Center for Innovative Oncology, National Cancer Center Hospital East
  • 2016  Unit Head, Division of Functional Imaging, Exploratory Oncology Research and Clinical Trail Center, National Cancer Center

Major affiliated societies

  • American Association for Cancer Research
  • Society of Nuclear Medicine and Molecular Imaging
  • Japanese Cancer Association (councilor)
  • Japanese Society of Nuclear Medicine (councilor)
  • The pharmaceutical Society of Japan
  • Japanese Society of Molecular imaging
  • The Japan Society of Drug Delivery System


  1. Ito K, Hamamichi S, Asano M, Hori Y, Matsui J, Iwata M, Funahashi Y, Umeda IO, Fujii H. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models. Cancer Sci, 107:60-67, 2016
  2. Araki K, Mizokami D, Tomifuji M, Yamashita T, Ohnuki K, Umeda IO, Fujii H, Kosuda S, Shiotani A. Novel Indocyanine Green-Phytate Colloid Technique for Sentinel Node Detection in Head and Neck: Mouse Study. Otolaryngol Head Neck Surg, 151:279-285, 2014
  3. Ogawa M, Umeda IO, Kosugi M, Kawai A, Hamaya Y, Takashima M, Yin H, Kudoh T, Seno M, Magata Y. Development of 111In-labeled liposomes for vulnerable atherosclerotic plaque imaging. J Nucl Med, 55:115-120, 2014
  4. Yoshimoto M, Hayakawa T, Mutoh M, Imai T, Tsuda K, Kimura S, Umeda IO, Fujii H, Wakabayashi K. In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. J Nucl Med, 53:765-771, 2012
  5. Umeda IO, Tani K, Tsuda K, Kobayashi M, Ogata M, Kimura S, Yoshimoto M, Kojima S, Moribe K, Yamamoto K, Moriyama N, Fujii H. High resolution SPECT imaging for visualization of intratumoral heterogeneity using a SPECT/CT scanner dedicated for small animal imaging. Ann Nucl Med, 26:67-76, 2012